Actively Recruiting
Total Infectome Characterization of Eye Infections
Led by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2025-07-17
200
Participants Needed
1
Research Sites
105 weeks
Total Duration
On this page
Sponsors
S
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor
S
Shanghai Fourth People's Hospital Tongji University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Multiple pathogens can cause eye infection. In recent years, emerging and resurging viral infections represent an important public health problem. Many emerging viruses cause infectious diseases involving ophthalmic manifestations, including Mpox virus, Zika, Ebola, and SARS-CoV-2. Broad and unbiased pathogen surveillance is essential, so we design this unbiased metagenomic sequencing based study to investigate the total infectome of eye infections. The study is historical and prospective in design.
CONDITIONS
Official Title
Total Infectome Characterization of Eye Infections
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a clinical diagnosis of one or more types of eye infections including acute conjunctivitis, keratitis, uveitis, and endophthalmitis
- Biological samples have been collected for clinical microbiological examination or consented to participate in this study
You will not qualify if you...
- Patients who have no historically clinical surplus specimens
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai General Hospital
Shanghai, Shanghai Municipality, China, 200030
Actively Recruiting
Research Team
M
Mei Kang, MPH
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here